Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on ...

CVS Health will drop the weight-loss drug Zepbound from its insured pharmacy options this summer. Employers and insurers may ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.

Eli Lilly's stock wobbled Thursday after a looming ... become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Eli Lilly’s stock wobbled Thursday after a ... become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded. This could complicate ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...